Home › Interpace's ThyraMir Receives Coverage From UnitedHealthcare

Interpace's ThyraMir Receives Coverage From UnitedHealthcare

Apr 18, 2017

NEW YORK (GenomeWeb) – Interpace Diagnostics said today that its ThyraMir test for diagnosing thyroid cancer has received coverage from UnitedHealthcare.

With this coverage decision, ThyraMir is now covered for around 250 million patients nationwide, the company said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jan
30
Featured Webinar

A Long-Read vs. Short-Read Platform Comparison: Best NGS approaches for Microbiome Studies

Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.

Jan
30
Featured Webinar

A Long-Read vs. Short-Read Platform Comparison: Best NGS approaches for Microbiome Studies

Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.

What's Popular?

In Molecular Diagnostics

  1. Guardant Health to Develop Blood-Based CDx for AstraZeneca Drugs

  2. Exosome Diagnostics Suing Former Employee for IP Theft

  3. Curetis to Cut 30 Percent of Workforce as Part of Strategic Restructuring

  4. Black Women With Breast Cancer Fare Worse, TAILORx Analysis Confirms at SABCS

    Premium

  5. Guardant Health to Launch Cell-Free DNA Assay for Cancer Recurrence Monitoring in 2019

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.